



**A TORRENT
GROUP COMPANY**

May 11, 2026

BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

BSE Scrip Code: 506943

Stock Symbol: JBCHEPHARM

Dear Sir,

Sub: Outcome of meeting of Board of Directors

In compliance with Regulation 30(2) and Regulation 33(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular no. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, enclosed please find herewith the Integrated Filing (Financials) containing the:

1. Audited standalone financial results for the financial year ended on March 31, 2026 accompanied by Report issued by Deloitte Haskins & Sells LLP, Chartered Accountants, Statutory Auditors ("Auditor").
2. Audited consolidated financial results for the financial year ended on March 31, 2026 accompanied by Auditor's Report.
3. Declaration of Unmodified opinion on reports issued by Auditor, on the Audited standalone and consolidated financial results for the financial year ended March 31, 2026.
4. Related Party Transactions for the half year ended March 31, 2026.

Further submission of (i) The Statement on Deviation or Variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. and (ii) Disclosure of outstanding default on loans and debt securities, are not applicable for the quarter ended March 31, 2026.

The aforesaid financial results have been approved and taken on record by the Board of Directors at its meeting held today, which commenced at 6.15 p.m. and concluded at 6.56 p.m.

We request you to take this intimation on record.

Thanking you,
Yours faithfully,

For J. B. Chemicals & Pharmaceuticals Ltd.

**Sandeep Phadnis
Vice President –Secretarial
& Company Secretary**

INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL STANDALONE FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF J.B. CHEMICALS & PHARMACEUTICALS LIMITED

Opinion and Conclusion

We have (a) audited the Standalone Financial Results for the year ended March 31, 2026 and (b) reviewed the Standalone Financial Results for the quarter ended March 31, 2026 (refer 'Other Matters' section below), which were subject to limited review by us, both included in the accompanying "Statement of Standalone Financial Results for the Quarter and Year Ended March 31, 2026" of **J.B. CHEMICALS & PHARMACEUTICALS LIMITED** (the "Company"), (the "Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "LODR Regulations").

(a) Opinion on Annual Standalone Financial Results

In our opinion and to the best of our information and according to the explanations given to us, the Standalone Financial Results for the year ended March 31, 2026:

- i. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- ii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and other comprehensive loss and other financial information of the Company for the year then ended.

(b) Conclusion on Unaudited Standalone Financial Results for the quarter ended March 31, 2026

With respect to the Standalone Financial Results for the quarter ended March 31, 2026, based on our review conducted as stated in paragraph (b) of Auditor's Responsibilities section below, nothing has come to our attention that causes us to believe that the Standalone Financial Results for the quarter ended March 31, 2026, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



**Basis for Opinion on the Audited Standalone Financial Results for the year ended
March 31, 2026**

We conducted our audit in accordance with the Standards on Auditing ("SA"s) specified under section 143(10) of the Companies Act, 2013 (the "Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor's Responsibilities section below. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (the "ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial Results for the year ended March 31, 2026 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

Management's and Board of Directors' Responsibilities for the Statement

This Statement which includes the Standalone Financial Results is the responsibility of the Company's Board of Directors and has been approved by them for the issuance. The Standalone Financial Results for the year ended March 31, 2026 has been compiled from the related audited standalone financial statements. This responsibility includes the preparation and presentation of the Standalone Financial Results for the quarter and year ended March 31, 2026 that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Results that give a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Results, the Board of Directors is responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the financial reporting process of the Company.

h.

Auditor's Responsibilities

(a) Audit of the Standalone Financial Results for the year ended March 31, 2026

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results for the year ended March 31, 2026 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Standalone Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Standalone Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the LODR Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Annual Standalone Financial Results, including the disclosures, and whether the Annual Standalone Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.

9 h.

Materiality is the magnitude of misstatements in the Annual Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Standalone Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Standalone Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

(b) Review of the Standalone Financial Results for the quarter ended March 31, 2026

We conducted our review of the Standalone Financial Results for the quarter ended March 31, 2026 in accordance with the Standard on Review Engagements ("SRE") 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Other Matters

- The Statement includes the results for the Quarter ended March 31, 2026 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us. Our report on the Statement is not modified in respect of this matter.



For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



Sampada S Narvankar
Partner
(Membership No. 102911)
UDIN: 26102911XXENXJ7867

Place: Mumbai
Date: May 11, 2026



**A TORRENT
GROUP COMPANY**

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2026

(₹ in lakhs)

Particulars	Quarter ended			Year ended	
	31-03-2026	31-12-2025	31-03-2025	31-03-2026	31-03-2025
	Unaudited (Refer Note 9)	Unaudited	Unaudited (Refer Note 9)	Audited	Audited
1. Revenue from operations	83,643	99,091	90,134	3,88,989	3,72,292
2. Other income	1,024	1,689	1,353	5,528	3,474
3. Total income (1+2)	84,667	1,00,780	91,487	3,94,517	3,75,766
4. Expenses					
a) Cost of materials consumed	23,380	21,203	18,897	91,202	82,004
b) Purchases of stock-in-trade	9,757	9,171	10,413	41,815	41,665
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(7,902)	705	1,035	(11,096)	1,553
d) Employee benefits expense (Refer note 4)	18,392	17,946	16,612	72,243	64,679
e) Finance costs	133	159	93	459	912
f) Depreciation and amortisation expense	4,856	4,362	4,441	17,669	16,645
g) Other expenses	20,523	23,116	20,079	89,234	80,597
Total expenses	69,139	76,662	71,570	3,01,526	2,88,055
5. Profit before exceptional items and tax (3-4)	15,528	24,118	19,917	92,991	87,711
6. Exceptional item (Refer note 5)	2,718	-	-	2,718	-
7. Profit before tax (5-6)	12,810	24,118	19,917	90,273	87,711
8. Tax expense					
a) Current tax	3,872	5,808	4,560	22,498	19,370
b) Current tax (credit) for earlier years	(245)	-	(201)	(245)	(201)
c) Deferred tax - (credit) / Charge	(471)	383	578	610	3,288
Total tax expense	3,156	6,191	4,937	22,863	22,457
9. Net profit after tax (7-8)	9,654	17,927	14,980	67,410	65,254
10. Other comprehensive income/(loss)					
a) (i) Items that will not be reclassified to profit or loss	436	(133)	(13)	(358)	(592)
(ii) Income tax on items that will not be reclassified to profit or loss	(110)	34	3	90	149
b) (i) Items that will be reclassified to profit or loss	-	-	359	(78)	128
(ii) Income tax on items that will be reclassified to profit or loss	-	-	(90)	20	(32)
Total other comprehensive income/(loss) (net of tax)	326	(99)	259	(326)	(347)
11. Total comprehensive income after tax (9+10)	9,980	17,828	15,239	67,084	64,907
12. Paid-up equity share capital (face value ₹ 1/- each)	1,606	1,567	1,557	1,606	1,557
13. Other equity				4,02,165	3,36,163
14. Earnings per share (face value ₹ 1/- each)					
a) Basic (₹)	*6.05	*11.45	*9.63	42.91	42.00
b) Diluted (₹)	*6.02	*11.29	*9.44	42.23	41.16
*Not Annualised					

Standalone statement of assets and liabilities as at March 31, 2026:

(₹ in lakhs)

Particulars	As at	As at
	31-03-2026	31-03-2025
	Audited	Audited
A. ASSETS		
1. Non-current assets		
(a) Property, plant and equipment	58,830	58,939
(b) Right-of-use assets	1,794	1,721
(c) Capital work-in-progress	6,116	4,596
(d) Goodwill	432	432
(e) Intangible assets	1,18,589	1,27,237
(f) Intangible assets under development	1,264	1,573
(g) Financial assets		
(i) Investments	16,891	17,086
(ii) Loans	21	35
(iii) Others financial assets	2,228	25,581
(h) Current tax assets (net)	3,666	1,172
(i) Other non-current assets	787	1,552
Total non-current assets	2,10,618	2,39,924
2. Current assets		
(a) Inventories	64,338	47,164
(b) Financial assets		
(i) Investments	73,891	31,711
(ii) Trade receivables	71,171	76,809
(iii) Cash and cash equivalents	2,636	7,621
(iv) Bank balances other than cash and cash equivalents	3,569	1,436
(v) Loans	54	55
(vi) Other financial assets	38,431	1,856
(c) Other current assets	17,642	11,214
Total current assets	2,71,732	1,77,866
Total assets	4,82,350	4,17,790
B. EQUITY AND LIABILITIES		
1. Equity		
(a) Equity share capital	1,606	1,557
(b) Other equity	4,02,165	3,36,163
Total equity	4,03,771	3,37,720
2. Liabilities		
Non-current liabilities		
(a) Financial liabilities		
(i) Lease liabilities	107	592
(b) Provisions	2,898	2,219
(c) Deferred tax liabilities (net)	19,125	18,625
(d) Other non-current liabilities	358	190
Total non-current liabilities	22,488	21,626
Current liabilities		
(a) Financial liabilities		
(i) Lease liabilities	167	650
(ii) Trade payables		
-Total outstanding dues of micro enterprises and small enterprises	5,149	3,700
-Total outstanding dues of creditors other than micro enterprises and small enterprises	31,944	34,759
(iii) Other financial liabilities	8,619	10,523
(b) Other current liabilities	3,194	2,148
(c) Provisions	6,134	5,918
(d) Current tax liabilities (net)	884	746
Total current liabilities	56,091	58,444
Total liabilities	78,579	80,070
Total equity and liabilities	4,82,350	4,17,790

Standalone statement of cash flows for the year ended March 31, 2026:

(₹ in lakhs)

Particulars	Year ended	
	31-03-2026	31-03-2025
	Audited	Audited
A. Cash flows from operating activities		
Profit before tax	90,273	87,711
Adjustments for :		
Depreciation and amortisation expense	17,669	16,645
Unrealised foreign exchange (gain) (net)	(395)	(339)
Finance costs	459	912
Share-based payment expense	6,860	5,348
Allowances for credit losses (net) (including credit impaired)	2,050	415
Net (gain) on sale/disposal of property, plant and equipment	(32)	(14)
Net (gain) on sale of current investments carried at fair value through profit or loss (net)	(1,445)	(2,683)
Fair value (gain) on financial instruments carried at fair value through profit or loss (net)	(1,072)	(538)
Interest income	(2,971)	(213)
Dividend income	(0)	(1)
Government grants	(118)	(125)
Discontinuance of lease assets	(84)	-
Operating profit before working capital changes	1,11,194	1,07,118
Adjustments for working capital:		
(Increase) in inventories	(17,175)	(1,044)
(Increase) in trade and other receivables	(3,301)	(6,614)
(Decrease) / Increase in trade payables, provisions and other liabilities	(1,619)	8,228
Cash generated from operations	89,099	1,07,688
Income taxes paid (including tax deducted at source and net of refunds)	(24,610)	(19,284)
Net cash generated from operating activities	64,489	88,404
B. Cash flows from investing activities		
Purchase of property, plant and equipment	(8,014)	(9,608)
Purchase of intangible assets (including intangible assets under development)	-	(1,470)
Proceeds from sale of property, plant and equipment	151	75
Purchase of current investments	(2,27,397)	(97,996)
Proceeds from sale of current investments	1,87,930	1,05,544
Change in other bank balances	(11,965)	(25,673)
Interest received	573	134
Dividend received	0	1
Net cash (used in) investing activities	(58,722)	(28,993)
C. Cash flows from financing activities		
Proceeds from issue of equity shares (ESOSs) options	23,196	2,400
Repayment of current borrowings (net)	-	(34,238)
Payment of lease liabilities	(2,411)	(1,165)
Finance costs	(223)	(719)
Dividend paid	(31,329)	(23,704)
Net cash (used in) financing activities	(10,767)	(57,426)
Net decrease in cash and cash equivalents (A+B+C)	(5,000)	1,985
Cash and cash equivalents at the beginning of the year	7,621	5,637
Exchange difference on restatement of foreign currency cash and cash	15	(1)
Cash and cash equivalents as at the end of the year	2,636	7,621

Mf

Notes:

1. The above standalone financial results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on May 11, 2026. The statutory auditors have carried out an audit of the standalone financial results for the year ended March 31, 2026 and a limited review of the standalone financials results of the Company for the quarter ended March 31, 2026. The results of the Company are available for investors at www.jbpharma.com, www.nseindia.com and www.bseindia.com.

2. These standalone financial results have been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules 2015 (as amended) ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

3. The Board of Directors of the Company has, at its meeting held on June 29, 2025, approved the proposed Scheme of Amalgamation of the Company with Torrent Pharmaceuticals Limited ("Transferee Company") and their respective shareholders, pursuant to Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 ("Act") The proposed scheme is subject to approval of the Hon'ble National Company Law Tribunal, Ahmedabad Bench ("NCLT")

In terms of the proposed scheme, the shareholders of the Company (other than the Transferee Company) shall be allotted equity shares of Transferee Company as per share exchange ratio i.e. 51 (fifty one) equity shares of the Transferee Company for every 100 (one hundred) equity shares held in the Company, as determined by registered independent valuer.

The Company and Torrent Pharmaceuticals Limited received No objection Letters from BSE Limited and National Stock Exchange of India Limited on February 17, 2026. Pursuant to NCLT's order dated March 23, 2026 and March 24, 2026, the meeting of equity shareholders of the Company and of the Transferee Company was held on April 28, 2026 through video conferencing. The proposed scheme, including the Share Exchange ratio, was duly approved by the Equity Shareholders of the Company and of the Transferee Company with requisite majority under the provisions of Section 230(6) of the Act, Further, in terms of SEBI Master Circular No. SEBI/HO/CFD/POD-2/P/CIR/2023/93 dated June 20, 2023 issued by the Securities and Exchange Board of India, the proposed scheme is approved by requisite majority of the public shareholders of the Company. The Company and the Transferee Company has filed a joint petition with NCLT seeking its approval on the proposed scheme. The Appointed Date for the proposed scheme is January 21st 2026. The Appointed Date for the proposed scheme is January 21st 2026. After approval of the merger by the NCLT and filing of the order with the authorities, the Company shall stand amalgamated with the Transferee Company.

4. The employee benefits expense during the quarters ended on March 31, 2026, December 31, 2025, March 31, 2025, for the year ended March 31, 2026 and for the year ended March 31, 2025, includes charge of ₹ 2,864 lakhs, ₹ 925 lakhs, ₹ 1,352 lakhs, ₹ 6,860 lakhs and ₹ 5,348 lakhs respectively, towards equity-settled share-based payment transactions in terms of Ind AS 102 - 'Share-based Payment'.

5. Exceptional items during the quarter and year ended includes -

- i) Severance compensation of Rs. 1,872.82 Lakhs, incurred on account of restructuring of the distribution network and
- ii) **Impact of New Labour Code-** The Government of India has consolidated multiple existing labour legislation into unified framework comprising four Labour codes collectively referred to as the "New Labour Codes", effective Nov 21, 2025. The Company has assessed the financial implications of these changes which has resulted in increase in gratuity liability arising from past service cost amounting to Rs. 845 lakhs. The Company continues to monitor the developments pertaining to Labour Codes and will evaluate impact if any on the measurement of the employee benefits liability.

6. The paid-up equity share capital of Company during the quarter ended on March 31, 2026 and for the year ended March 31, 2025 stands increased by ₹ 39.08 lakhs and ₹ 48.81 lakhs upon allotment of 3,907,750 and 48,81,498 equity shares of ₹ 1 each pursuant to "ESOS Scheme".

7. The Board of Directors at its meeting held on May 11, 2026, have recommended a final dividend of ₹ 9.30 per equity share of ₹ 1 each for the year 2025-26.

8. The Company has only one reportable business segment viz. "Pharmaceuticals".

9. The figures for the quarters ended March 31, 2026 and March 31, 2025 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures upto nine months ended December 31 of the relevant financial year.


10. Amount less than ₹ 50,000/- is presented as ₹ 0.00 Lakhs.

h.

Mumbai

May 11, 2026

By order of the Board
For J.B. Chemicals & Pharmaceuticals Limited



Sudhir Menon
Director



INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL CONSOLIDATED FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF J.B. CHEMICALS & PHARMACEUTICALS LIMITED

Opinion and Conclusion

We have (a) audited the Consolidated Financial Results for the year ended March 31, 2026 and (b) reviewed the Consolidated Financial Results for the quarter ended March 31, 2026 (refer paragraph (b) of 'Other Matters' section below), which were subject to limited review by us, both included in the accompanying "Statement of Consolidated Financial Results for the Quarter and Year Ended March 31, 2026" of **J.B. CHEMICALS & PHARMACEUTICALS LIMITED** (the "Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as the "Group"), (the "Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "LODR Regulations").

(a) Opinion on Annual Consolidated Financial Results

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the audit reports of the other auditors on separate financial statements of the subsidiaries referred to in paragraph (b) of Other Matters section below, the Consolidated Financial Results for the year ended March 31, 2026:

- (i) includes the financial results of the following entities:

Parent – J.B. Chemicals & Pharmaceuticals Limited

Direct Subsidiaries – OOO Unique Pharmaceutical Laboratories; and
Unique Pharmaceutical Laboratories FZE.

Step Down Subsidiaries – Biotech Laboratories (Pty.) Ltd.; and
JBCPL Philippines Inc.

- (ii) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- (iii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the consolidated net profit and consolidated other comprehensive income and other financial information of the Group for the year ended March 31, 2026.

(b) Conclusion on Unaudited Consolidated Financial Results for the quarter ended March 31, 2026

With respect to the Consolidated Financial Results for the quarter ended March 31, 2026, based on our review conducted and procedures performed as stated in paragraph (b) of Auditor's Responsibilities section below and based on the

consideration of the review reports of the other auditors referred to in paragraph (b) of Other Matters section below, nothing has come to our attention that causes us to believe that the Consolidated Financial Results for the quarter ended March 31, 2026, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Basis for Opinion on the Audited Consolidated Financial Results for the year ended March 31, 2026

We conducted our audit in accordance with the Standards on Auditing ("SA"s) specified under section 143(10) of the Companies Act, 2013 (the "Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor's Responsibilities section below. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (the "ICAI") together with the ethical requirements that are relevant to our audit of the Consolidated Financial Results for the year ended March 31, 2026 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us and the audit evidence obtained by the other auditors in terms of their reports referred to in paragraph (b) of Other Matters section below, is sufficient and appropriate to provide a basis for our audit opinion.

Management's and Board of Directors' Responsibilities for the Statement

This Statement, which includes the Consolidated Financial Results is the responsibility of the Parent's Board of Directors and has been approved by them for the issuance. The Consolidated Financial Results for the year ended March 31, 2026, has been compiled from the related audited consolidated financial statements. This responsibility includes the preparation and presentation of the Consolidated Financial Results for the quarter and year ended March 31, 2026 that give a true and fair view of the consolidated net profit and consolidated other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards, prescribed under section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations.

The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the respective financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of this Consolidated Financial Results by the Directors of the Parent, as aforesaid.

In preparing the Consolidated Financial Results, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the respective entities to continue as a going concern, disclosing, as applicable, matters related to going

g h.

concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate their respective entities or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities

(a) Audit of the Consolidated Financial Results for the year ended March 31, 2026

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Results for the year ended March 31, 2026 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Consolidated Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Consolidated Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the LODR Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.

9 h.

- Evaluate the overall presentation, structure and content of the Annual Consolidated Financial Results, including the disclosures, and whether the Annual Consolidated Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Perform procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the LODR Regulations to the extent applicable.
- Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Results of the entities within the Group to express an opinion on the Annual Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of such entities included in the Annual Consolidated Financial Results of which we are the independent auditors. For the other entities included in the Annual Consolidated Financial Results, which have been audited by the other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

Materiality is the magnitude of misstatements in the Annual Consolidated Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Consolidated Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Consolidated Financial Results.

We communicate with those charged with governance of the Parent and such other entities included in the Consolidated Financial Results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

(b) Review of the Consolidated Financial Results for the quarter ended March 31, 2026

We conducted our review of the Consolidated Financial Results for the quarter ended March 31, 2026 in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

The Statement includes the results of the entities as listed under paragraph (a)(i) of Opinion and Conclusion section above.

ah

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

Other Matters

- (a) The Statement includes the results for the quarter ended March 31, 2026 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us. Our report is not modified in respect of this matter.
- (b) We did not audit the financial statements of 4 subsidiaries included in the consolidated financial results, whose financial statements reflect total assets of Rs. 45,328.85 Lakhs as at March 31, 2026 and total revenues of Rs. 10,890.92 Lakhs and Rs. 40,893.83 Lakhs for the quarter and year ended March 31, 2026 respectively, total net profit after tax of Rs. 380.22 Lakhs and Rs. 2,645.19 Lakhs for the quarter and year ended March 31, 2026 respectively and other comprehensive income of Rs. 30.51 Lakhs and Rs. 14.14 Lakhs for the quarter and year ended March 31, 2026 respectively and net cash inflows of Rs. 4,494.03 Lakhs for the year ended March 31, 2026, as considered in the Statement. These financial statements have been audited by other auditors whose reports have been furnished to us by the Management and our opinion and conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of the other auditors and the procedures performed by us as stated under Auditor's Responsibilities section above.

Our report on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors.

h-

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



Sampada S Narvankar
Partner
(Membership No. 102911)
UDIN: 26102911GSEVNQ5557

Place: Mumbai
Date: May 11, 2026



A TORRENT GROUP COMPANY

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2026

(₹ in lakhs)

Particulars	Quarter ended			Year ended	
	31-03-2026	31-12-2025	31-03-2025	31-03-2026	31-03-2025
	Unaudited (Refer Note 9)	Unaudited	Unaudited (Refer Note 9)	Audited	Audited
1. Revenue from operations	90,423	1,06,472	94,948	4,14,779	3,91,799
2. Other income	1,198	1,828	1,448	6,015	3,832
3. Total income (1+2)	91,621	1,08,300	96,396	4,20,794	3,95,631
4. Expenses					
a) Cost of materials consumed	23,371	21,201	18,897	91,244	82,003
b) Purchases of stock-in-trade	10,282	10,434	13,596	47,790	49,695
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(6,228)	1,308	(329)	(9,407)	(43)
d) Employee benefits expense (Refer note 4)	19,873	19,142	17,682	77,270	68,761
e) Finance costs	123	188	145	557	1,173
f) Depreciation and amortisation expense	5,001	4,535	4,644	18,250	17,104
g) Other expenses	23,012	24,805	22,458	97,139	88,199
Total expenses	75,434	81,613	77,093	3,22,843	3,06,892
5. Profit before exceptional items and tax (3-4)	16,187	26,687	19,303	97,951	88,739
6. Exceptional item (Refer Note 5)	2,718	-	-	2,718	-
7. Profit before tax (5-6)	13,469	26,687	19,303	95,233	88,739
8. Tax expense					
a) Current tax	4,016	6,313	4,799	23,473	20,242
b) Current tax (credit) for earlier years	(245)	-	(201)	(245)	(201)
c) Deferred tax - (credit) / Charge	(439)	585	136	1,058	2,740
Total tax expense	3,332	6,898	4,734	24,286	22,781
9. Net profit after tax (7-8)	10,137	19,789	14,569	70,947	65,958
10. Other comprehensive income/(loss)					
a) (i) Items that will not be reclassified to profit or loss	436	(133)	(13)	(357)	(592)
(ii) Income tax on items that will not be reclassified to profit or loss	(110)	34	3	90	149
b) (i) Items that will be reclassified to profit or loss	414	1,094	1,486	2,927	1,356
(ii) Income tax on items that will be reclassified to profit or loss	(10)	6	(117)	16	(59)
Total other comprehensive income/(loss) (net of tax)	730	1,001	1,359	2,676	854
11. Total comprehensive income after tax (9+10)	10,867	20,790	15,928	73,623	66,812
12. Net profit after tax for the period/year attributable to:					
a) Owners of the company	10,137	19,789	14,569	70,947	65,958
b) Non-controlling interest	-	-	-	-	-
13. Other comprehensive income/(loss) for the period/year attributable					
a) Owners of the company	730	1,001	1,359	2,676	854
b) Non-controlling interest	-	-	-	-	-
14. Total comprehensive income attributable to :					
a) Owners of the company	10,867	20,790	15,928	73,623	66,812
b) Non-controlling interest	-	-	-	-	-
15. Paid-up equity share capital (face value ₹ 1/- each)	1,606	1,567	1,557	1,606	1,557
16. Other equity				4,14,316	3,41,775
17. Earnings per share (face value ₹ 1/- each)					
a) Basic (₹)	*6.35	*12.63	*9.36	45.16	42.45
b) Diluted (₹)	*6.32	*12.45	*9.17	44.45	41.56
*Not Annualised					

Particulars	As at	As at
	31-03-2026	31-03-2025
	Audited	Audited
A. ASSETS		
1. Non-current assets		
(a) Property, plant and equipment	59,286	59,133
(b) Right-of-use assets	1,877	1,861
(c) Capital work-in-progress	6,116	4,670
(d) Goodwill	5,746	5,746
(e) Intangible assets	1,21,634	1,30,079
(f) Intangible assets under development	1,277	1,635
(g) Financial assets		
(i) Investments	2,603	2,798
(ii) Loans	21	35
(iii) Others financial assets	2,228	25,581
(h) Deferred tax assets (net)	687	842
(i) Current tax assets (net)	3,666	1,172
(j) Other non-current assets	787	1,552
Total non-current assets	2,05,928	2,35,104
2. Current assets		
(a) Inventories	68,340	52,895
(b) Financial assets		
(i) Investments	73,891	31,711
(ii) Trade receivables	78,091	81,538
(iii) Cash and cash equivalents	11,018	11,509
(iv) Bank balances other than cash and cash equivalents	3,569	1,436
(v) Loans	54	55
(vi) Other financial assets	37,751	1,447
(c) Other current assets	18,223	11,683
Total current assets	2,90,937	1,92,274
Total assets	4,96,865	4,27,378
B. EQUITY AND LIABILITIES		
1. Equity		
(a) Equity share capital	1,606	1,557
(b) Other equity	4,14,316	3,41,775
Total Equity	4,15,922	3,43,332
2. Liabilities		
Non-current liabilities		
(a) Financial liabilities		
(i) Lease liabilities	112	636
(b) Provisions	2,937	2,253
(c) Deferred tax liabilities (net)	18,418	17,734
(d) Other non-current liabilities	358	190
Total non-current liabilities	21,825	20,813
Current liabilities		
(a) Financial liabilities		
(i) Borrowings	-	1,380
(ii) Lease liabilities	248	773
(iii) Trade payables		
-Total outstanding dues of micro enterprises and small enterprises	5,149	3,700
-Total outstanding dues of creditors other than micro enterprises and small enterprises	33,949	37,372
(iv) Other financial liabilities	9,017	10,731
(b) Other current liabilities	3,308	2,228
(c) Provisions	6,527	6,226
(d) Current tax liabilities (net)	920	823
Total current liabilities	59,118	63,233
Total liabilities	80,943	84,046
Total equity and liabilities	4,96,865	4,27,378

Particulars	Year ended	
	31-03-2026	31-03-2025
	Audited	Audited
A. Cash flows from operating activities		
Profit before tax	95,233	88,739
Adjustments for :		
Depreciation and amortisation expense	18,250	17,104
Unrealised foreign exchange loss (net)	2,005	560
Finance costs	557	1,173
Share-based payment expense	7,101	5,490
Allowances for credit losses (net) (including credit impaired)	2,152	429
Net (gain) on sale/disposal of property, plant and equipment	(57)	(21)
Net (gain) on sale of current investments carried at fair value through profit or loss	(1,445)	(2,683)
Fair value (gain) on financial instruments carried at fair value through profit or loss (net)	(1,072)	(538)
Interest income	(3,374)	(533)
Dividend income	(0)	(1)
Government grants	(118)	(125)
Discontinuance of lease assets	(84)	-
Operating profit before working capital changes	1,19,148	1,09,594
Adjustments for working capital:		
(Increase) in inventories	(15,445)	(2,644)
(Increase) in trade and other receivables	(5,658)	(4,980)
(Decrease)/Increase in trade payables, provisions and other liabilities	(2,027)	8,342
Cash generated from operations	96,018	1,10,312
Income taxes paid (including tax deducted at source and net of refunds)	(25,625)	(20,067)
Net cash generated from operating activities	70,393	90,245
B. Cash flows from investing activities		
Purchase of property, plant and equipment	(8,319)	(9,759)
Purchase of intangible assets (including intangible assets under development)	-	(2,271)
Proceeds from sale of property, plant and equipment	186	111
Purchase of current investments	(2,27,397)	(97,996)
Proceeds from sale of current investments	1,87,930	1,05,544
Change in other bank balances	(11,965)	(25,673)
Interest received	977	454
Dividend received	0	1
Net cash (used in) investing activities	(58,588)	(29,589)
C. Cash flows from financing activities		
Proceeds from issue of equity shares (ESOSs) options	23,196	2,400
(Repayment of) current borrowings (net)	(1,380)	(34,392)
Payment of lease liabilities	(2,493)	(1,310)
Finance costs	(305)	(962)
Dividend paid	(31,329)	(23,704)
Net cash (used in) financing activities	(12,311)	(57,968)
Net (decrease)/increase in cash and cash equivalents (A+B+C)	(506)	2,688
Cash and cash equivalents at the beginning of the year	11,509	8,822
Exchange difference on restatement of foreign currency cash and cash equivalents	15	(1)
Cash and cash equivalents at the end of the year	11,018	11,509

h.

AF

Notes:

1. The above consolidated financial results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on May 11, 2026. The statutory auditors have carried out an audit of the consolidated financial results for the year ended March 31, 2026 and a limited review of the consolidated financials results of the Company for the quarter ended March 31, 2026. The results of the Company are available for investors at www.jbpharma.com, www.nseindia.com and www.bseindia.com.

2. These consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules 2015 (as amended) ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

3. The Board of Directors of the Holding Company has, at its meeting held on June 29, 2025, approved the proposed Scheme of Amalgamation of the Holding Company with Torrent Pharmaceuticals Limited ("Transferee Company") and their respective shareholders, pursuant to Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 ("Act") The proposed scheme is subject to approval of the Hon'ble National Company Law Tribunal, Ahmedabad Bench ("NCLT")

In terms of the proposed scheme, the shareholders of the Holding Company (other than the Transferee Company) shall be allotted equity shares of Transferee Company as per share exchange ratio i.e. 51 (fifty one) equity shares of the Transferee Company for every 100 (one hundred) equity shares held in the Holding Company, as determined by registered independent valuer.

The Holding Company and Torrent Pharmaceuticals Limited received No objection Letters from BSE Limited and National Stock Exchange of India Limited on February 17, 2026. Pursuant to NCLT's order dated March 23, 2026 and March 24, 2026, the meeting of equity shareholders of the Holding Company and of the Transferee Company was held on April 28, 2026 through video conferencing. The proposed scheme, including the Share Exchange ratio, was duly approved by the Equity Shareholders of the Holding Company and of the Transferee Company with requisite majority under the provisions of Section 230(6) of the Act, Further, in terms of SEBI Master Circular No. SEBI/HO/CFD/POD-2/P/CIR/2023/93 dated June 20, 2023 issued by the Securities and Exchange Board of India, the proposed scheme is approved by requisite majority of the public shareholders of the Holding Company. The Holding Company and the Transferee Company has filed a joint petition with NCLT seeking its approval on the proposed scheme. The Appointed Date for the proposed scheme is January 21st 2026. After approval of the merger by the NCLT and filing of the order with the authorities, the Holding Company shall stand amalgamated with the Transferee Company.

4. The employee benefits expense during the quarters ended on March 31, 2026, December 31, 2025, March 31, 2025, for the year ended March 31, 2026 and for the year ended March 31, 2025, includes charge of ₹ 2,998 lakhs, ₹ 954 lakhs, ₹ 1,387 lakhs, ₹ 7,101 lakhs and ₹ 5,490 lakhs respectively, towards equity-settled share-based payment transactions in terms of Ind AS 102 - 'Share-based Payment'.

5. Exceptional items during the quarter and year ended includes-

i) Severance compensation of Rs. 1,872.82 Lakhs, incurred on account of restructuring of the distribution network and

ii) **Impact of New Labour Code-** The Government of India has consolidated multiple existing labour legislation into unified framework comprising four Labour codes collectively referred to as the "New Labour Codes", effective Nov 21, 2025. The Company has assessed the financial implications of these changes which has resulted in increase in gratuity liability arising from past service cost amounting to Rs. 845 lakhs. The Holding Company continues to monitor the developments pertaining to Labour Codes and will evaluate impact if any on the measurement of the employee benefits liability.

6. The paid-up equity share capital of Holding Company during the quarter ended on March 31 2026 and for the year ended March 31, 2026 stands increased by ₹ 39.08 lakhs and ₹ 48.81 lakhs upon allotment of 3,907,750 and 48,81,498 equity shares of ₹ 1 each pursuant to "ESOS Scheme".

7. The Board of Directors of the Holding Company, at its meeting held on May 11, 2026, have recommended a final dividend of ₹ 9.30 per equity share of ₹ 1 each for the year 2025-26.

8. The Group has only one reportable business segment viz. "Pharmaceuticals".

9. The figures for the quarters ended March 31, 2026 and March 31, 2025 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures upto nine months ended December 31 of the relevant financial year.

10. Amount less than ₹ 50,000/- is presented as ₹ 0.00 Lakhs.

h

Mumbai
May 11, 2026

By order of the Board
For J.B. Chemicals & Pharmaceuticals Limited

Sudhir Menon
Director

dl

At



**A TORRENT
GROUP COMPANY**

FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS

Related party transactions entered during the half year ended on March 31, 2026 is as under.

(Rs. in lakhs)

S. No	Details of the party (listed entity /subsidiary) entering into the transaction	Details of the counterparty		Type of related party transaction	Value of the related party transaction as approved by the audit committee/ Board for FY26	Value of transaction during the reporting period half year ended March 2026	In case amount are due to either party as a result of the transaction	
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance	Closing balance
1.	J. B. Chemicals & Pharmaceuticals Limited	OOO Unique Pharmaceutical Laboratories	Subsidiary	Sale of goods	6,500.00	2,148.92	4,205.10	3,605.22
2.	J. B. Chemicals & Pharmaceuticals Limited	OOO Unique Pharmaceutical Laboratories	Subsidiary	Marketing Service Fees paid	3,221.02	2,030.32	(467.56)	(616.14)
3.	J. B. Chemicals & Pharmaceuticals Limited	OOO Unique Pharmaceutical Laboratories	Subsidiary	Regulatory Filing and Product Registration fees	500.00	280.00	-	-
4.	J. B. Chemicals & Pharmaceuticals Limited	OOO Unique Pharmaceutical Laboratories	Subsidiary	Guarantee Commission	20.00	11.83	-	11.80
5.	J. B. Chemicals & Pharmaceuticals Limited	OOO Unique Pharmaceutical Laboratories	Subsidiary	Recovery of expenses	25.00	14.98	-	14.95
6.	J. B. Chemicals & Pharmaceuticals Limited	Unique Pharmaceutical Laboratories FZE	Subsidiary	Sale of goods	1,800.00	381.15	47.59	452.60
7.	J. B. Chemicals & Pharmaceuticals Limited	Unique Pharmaceutical Laboratories FZE	Subsidiary	Compensation Cost- ESOP	122.74	86.56	201.99	304.91
8.	J. B. Chemicals & Pharmaceuticals Limited	Unique Pharmaceutical Laboratories FZE	Subsidiary	Compensation Cost- ESOP	119.90	80.42	308.12	407.24
9.	J. B. Chemicals & Pharmaceuticals Limited	Unique Pharmaceutical Laboratories FZE	Subsidiary	Marketing Support Service	770.00	397.54	(49.94)	(35.98)
10.	J. B. Chemicals & Pharmaceuticals Limited	JBCPL Philippines Inc.	Subsidiary	Transfer of Certificate of Product registration (CPR)	65.00	-	27.61	29.44

Registered Office:

J. B. Chemicals & Pharmaceuticals Limited
CIN: L24390GJ1976PLC173077
302, Iscon Mall, Star India Bazar Building,
Opp. Jodhpur BRTS Satellite,
Ahmedabad- 380015, Gujarat, India
Email: secretarial@jbpharma.com

Corporate Office:

J. B. Chemicals & Pharmaceuticals Limited
CIN: L24390GJ1976PLC173077
Energy IT Park, Unit A, 3rd Floor, Appa Saheb Marathe Marg,
Prabhadevi, Mumbai 400 025.
Tel.:+91 22 2439 5200/5500



**A TORRENT
GROUP COMPANY**

11.	J. B. Chemicals & Pharmaceuticals Limited	Biotech Laboratories (Pty.) limited	Subsidiary	Sale of goods	9,950.00	3,622.59	983.85	688.17
12.	J. B. Chemicals & Pharmaceuticals Limited	Biotech Laboratories (Pty.) limited	Subsidiary	Technical Service fee and DAP charges	500.00	168.59	153.95	69.78
13.	JBCPL Philippines Inc	Unique Pharmaceutical Laboratories FZE	Subsidiary	Payment of expenses	200.00	50.25	194.95	126.25
14.	J. B. Chemicals & Pharmaceuticals Limited	Dadra and Nagar Haveli and Daman and Diu Power Distribution Corporation Limited	Group Company	Purchase of electricity	156.29	156.29	-	-
15.	J. B. Chemicals & Pharmaceuticals Limited	Dadra and Nagar Haveli and Daman and Diu Power Distribution Corporation Limited	Group Company	Fixed Deposit	-	-	-	66.20
16.	J. B. Chemicals & Pharmaceuticals Limited	Dadra and Nagar Haveli and Daman and Diu Power Distribution Corporation Limited	Group Company	Bank Guarantee	-	-	-	347.45
17.	J. B. Chemicals & Pharmaceuticals Limited	Torrent Pharmaceuticals Limited	Holding Company	Sale of Material	1,300.00	235.74	0	277.66
	Total					9,665.18	5,605.66	5,749.55

Registered Office:

J. B. Chemicals & Pharmaceuticals Limited
CIN: L24390GJ1976PLC173077
302, Iscon Mall, Star India Bazar Building,
Opp. Jodhpur BRTS Satellite,
Ahmedabad- 380015, Gujarat, India
Email: secretarial@jbpharma.com

Corporate Office:

J. B. Chemicals & Pharmaceuticals Limited
CIN: L24390GJ1976PLC173077
Energy IT Park, Unit A, 3rd Floor, Appa Saheb Marathe Marg,
Prabhadevi, Mumbai 400 025.
Tel.: +91 22 2439 5200/5500



**A TORRENT
GROUP COMPANY**

May 11, 2026

BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

BSE Scrip Code : 506943

Stock Symbol: JBCHEPHARM

Dear Sir,

Sub: Declaration pursuant to SEBI notification No. SEBI/LAD-NRO/GN/2016-17/001 dated May 25, 2016 read with circular CIR/CFD/CMD/56/2016 dated May 27, 2016

This is to inform you that statutory auditors of the Company, Deloitte Haskins & Sells, Chartered Accountants, has issued their reports on the Audited standalone and consolidated financial results for the financial year ended March 31, 2026 with unmodified opinion.

We request you to take the above on record.

Thanking you,

Yours faithfully,
For J.B. Chemicals & Pharmaceuticals Ltd.

**Sandeep Phadnis
Vice President – Secretarial
& Company Secretary**

Registered Office:
J. B. Chemicals & Pharmaceuticals Limited
CIN: L24390GJ1976PLC173077
302, Iscon Mall, Star India Bazar Building,
Opp. Jodhpur BRTS Satellite,
Ahmedabad- 380015, Gujarat, India
Email: secretarial@jbpharma.com

Corporate Office:
J. B. Chemicals & Pharmaceuticals Limited
CIN: L24390GJ1976PLC173077
Energy IT Park, Unit A, 3rd Floor, Appa Saheb Marathe Marg,
Prabhadevi, Mumbai 400 025.
Tel.:+91 22 2439 5200/5500

www.jbpharma.com